Evgen Pharma focuses on healthy pipeline of clinical programmes

  • Evgen Pharma’s SFX-01 granted orphan drug designation by FDA for malignant glioma treatment
  • Evgen Pharma now has the financial runway to exploit its technology after ‘transformative’ City fundraiser
  • Market Report: FTSE gets jab of confidence as Moderna vaccine starts UK rollout

Quick facts: Evgen Pharma PLC


View company profile

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases. Our pipeline is derived from our proprietary Sulforadex(R) technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications.

02 Sep 2021

(, ) said its SFX-01 drug has been granted an orphan drug designation (OD) by the US Food and Drug Administration (FDA) for the treatment of malignant glioma.

The clinical stage drug development company submitted its application for OD designation on 13 July 2021.

Dr Huw Jones, CEO of Evgen, said: “We are delighted that our team and advisors have successfully gained Orphan Drug designation for SFX-01 in the USA in a very short period of time. This is part of a wider strategy to access the US market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering.”

Read more

13 Jul 2021

() announced progress for its lead asset on two fronts in the field of cancer.

In the US, it has applied to the Food & Drug Administration for orphan drug (OD) status for SFX-01 in the area of glioma, a brain cancer with a very poor prognosis.

Read more

09 Jul 2021

() will drill down into data from an important trial of its lead asset after the study was discontinued.

SFX-01 was assessed for its potential to treat community-acquired pneumonia, including patients with suspected Coronavirus (COVID-19) infection, as part of the phase II/III STAR trial in Dundee.

Read more

09 Mar 2021

‘Transformative’ is the word Huw Jones uses to describe the recent GBP11mln fundraising by ().

“It allows us to accelerate some substantial work now,” the company’s CEO says.

Read more

07 Apr 2021

The Market Report with Katie Pilbeam. FTSE 100 open strongly again on vaccine news and a switch in to duller, less cyclical stocks. The blue-chip index was up 62 to 6,885 in early trades.

shares rose 3% as retail investors were allowed to trade for the first time. Some 70,000 small investors bought shares in what has been dubbed the worst IPO ever.

Moderna’s Covid-19 vaccine has started to be rolled out in the UK making it the third version now being administered to people in Britain. Patients in Carmarthenshire in Wales were the first to receive the new vaccine.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…


Evgen portfolio update on core field of cancer, ‘the R&D is entirely on plan…

Evgen Pharma PLC’s (LON:EVG) Dr Huw Jones joins Proactive London to go through their portfolio with progress for is lead asset on two fronts in the field of cancer.

Jones firstly addresses the results of the ‘STAR’ Covid-19 trial of its lead asset, ‘SFX-01’ which was implemented as an…

on 21/7/21

2 min read


Please enter your comment!
Please enter your name here